Literature DB >> 12014438

Novel stachyflin derivatives from Stachybotrys sp. RF-7260. Fermentation, isolation, structure elucidation and biological activities.

Kazuyuki Minagawa1, Shuichi Kouzuki, Hiroyoshi Tani, Kikuo Ishii, Tatsuo Tanimoto, Yoshihiro Terui, Toshiyuki Kamigauchi.   

Abstract

Stachybotrys sp. RF-7260 was found to produce stachyflins, novel anti-influenza virus agents, under solid-state fermentation conditions. Feeding DL-lysine to a culture of Stachybotrys sp. RF-7260 induced the formation of the novel compounds, SQ-02-S-L2 and -L1, and feeding DL-valine the formation of SQ-02-S-VI and -V2. The structures of these metabolites were determined by detailed 2D NMR analyses in comparison with acetylstachyflin. SQ-02-S-L2 and -L1 have the lysine moiety and SQ-02-S-V1 has the valine moiety. SQ-02-S-V2 has an amidine moiety instead of the lactam moiety in acetylstachyflin. SQ-02-S-L2, -L1 and -V1, substituted on the lactam amide hydrogen, displayed only a low level of the antiviral activity. However, deacetyl SQ-02-S-V2 showed potent antiviral activity similar to stachyflin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014438     DOI: 10.7164/antibiotics.55.239

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  Sesquiterpenoids and xanthones derivatives produced by sponge-derived fungus Stachybotry sp. HH1 ZSDS1F1-2.

Authors:  Chun Qin; Xiuping Lin; Xin Lu; Junting Wan; Xuefeng Zhou; Shengrong Liao; Zhengchao Tu; Shihai Xu; Yonghong Liu
Journal:  J Antibiot (Tokyo)       Date:  2014-08-13       Impact factor: 2.649

Review 2.  Indoor mold, toxigenic fungi, and Stachybotrys chartarum: infectious disease perspective.

Authors:  D M Kuhn; M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

3.  Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes.

Authors:  Yurie Motohashi; Manabu Igarashi; Masatoshi Okamatsu; Takeshi Noshi; Yoshihiro Sakoda; Naoki Yamamoto; Kimihito Ito; Ryu Yoshida; Hiroshi Kida
Journal:  Virol J       Date:  2013-04-16       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.